|
ER status
|
PR status
|
HER2 status
|
ER, PR, and HER2 status number of women
|
ER, PR, and HER2 status row distribution (%)
|
---|
Number positive
|
Number negative
|
% ER negative
|
Number positive
|
Number negative
|
% PR negative
|
Number positive
|
Number negative
|
% HER2 positive
|
Luminal A
|
Luminal B
|
HER2P-enriched
|
TRN
|
Luminal A
|
Luminal B
|
HER2P-enriched
|
TRN
|
---|
All women
|
688
|
375
|
35.3†
|
559
|
499
|
47.2†
|
756
|
265
|
26.0†
|
545
|
149
|
116
|
209
|
53.5
|
14.6
|
11.4
|
20.5
|
Age
|
<40
|
100
|
54
|
35.1
|
84
|
71
|
45.8
|
102
|
48
|
32.0
|
77
|
29
|
19
|
25
|
51.3
|
19.3
|
12.7
|
16.7
|
40–49
|
177
|
85
|
32.4
|
148
|
113
|
43.3
|
173
|
77
|
30.8
|
128
|
47
|
30
|
45
|
51.2
|
18.8
|
12.0
|
18.0
|
50–59
|
149
|
121
|
44.8
|
107
|
162
|
60.2
|
199
|
59
|
22.9
|
123
|
28
|
31
|
75
|
47.9
|
10.9
|
12.1
|
29.2
|
60–69
|
134
|
58
|
30.2
|
106
|
83
|
43.9
|
141
|
42
|
23.0
|
109
|
22
|
20
|
31
|
59.9
|
12.1
|
11.0
|
17.0
|
70–79
|
90
|
41
|
31.3
|
82
|
49
|
37.4
|
96
|
31
|
24.4
|
74
|
19
|
12
|
22
|
58.3
|
15.0
|
9.5
|
17.3
|
≥80
|
38
|
16
|
29.6
|
32
|
21
|
39.6
|
45
|
8
|
15.1
|
34
|
4
|
4
|
11
|
64.2
|
7.6
|
7.6
|
20.8
|
Calendar year
|
2006–2007
|
86
|
60
|
41.1
|
72
|
72
|
50.0
|
87
|
37
|
29.8
|
66
|
16
|
21
|
21
|
53.2
|
12.9
|
16.9
|
16.9
|
2008–2009
|
241
|
144
|
37.4
|
186
|
198
|
51.6
|
263
|
116
|
30.6
|
183
|
65
|
51
|
80
|
48.3
|
17.2
|
13.5
|
21.1
|
2010–2012
|
361
|
171
|
32.1
|
301
|
229
|
43.2
|
406
|
112
|
21.6
|
296
|
68
|
44
|
108
|
57.4
|
13.2
|
8.5
|
20.9
|
Stage
|
I
|
43
|
13
|
23.2
|
41
|
16
|
28.1
|
40
|
14
|
25.9
|
34
|
10
|
4
|
6
|
63.0
|
18.5
|
7.4
|
11.1
|
II
|
319
|
130
|
29.0
|
262
|
184
|
41.3
|
345
|
95
|
21.6
|
262
|
60
|
35
|
81
|
59.8
|
13.7
|
8.0
|
18.5
|
III
|
271
|
202
|
42.7
|
218
|
254
|
53.8
|
314
|
133
|
29.8
|
207
|
68
|
65
|
107
|
46.3
|
15.2
|
14.5
|
23.9
|
IV
|
55
|
30
|
35.3
|
38
|
45
|
54.2
|
57
|
23
|
28.8
|
42
|
11
|
12
|
15
|
52.5
|
13.8
|
15.0
|
18.8
|
Tumor grade
|
1
|
89
|
12
|
11.9
|
76
|
25
|
24.8
|
84
|
15
|
15.2
|
76
|
12
|
3
|
8
|
76.7
|
12.1
|
3.0
|
8.1
|
2
|
331
|
109
|
24.8
|
278
|
161
|
36.7
|
332
|
96
|
22.4
|
276
|
60
|
36
|
55
|
64.6
|
14.1
|
8.4
|
12.9
|
3
|
189
|
207
|
52.3
|
148
|
246
|
62.4
|
264
|
125
|
32.1
|
138
|
61
|
64
|
125
|
35.6
|
15.7
|
16.5
|
32.2
|
Missing
|
79
|
47
|
37.3
|
57
|
67
|
54.0
|
76
|
29
|
27.6
|
55
|
16
|
13
|
21
|
52.4
|
15.2
|
12.4
|
20.0
|
Ethnicity
|
Black
|
606
|
351
|
36.7
|
492
|
461
|
48.4
|
679
|
240
|
23.1
|
481
|
131
|
109
|
196
|
52.5
|
14.3
|
11.9
|
20.4
|
White
|
32
|
8
|
20.0
|
27
|
13
|
32.5
|
29
|
9
|
23.7
|
24
|
7
|
2
|
5
|
63.2
|
18.4
|
5.3
|
13.2
|
Colored
|
30
|
9
|
23.1
|
26
|
13
|
33.3
|
30
|
8
|
21.1
|
26
|
5
|
3
|
4
|
68.4
|
13.2
|
7.9
|
10.5
|
Asian
|
15
|
5
|
36.7
|
12
|
8
|
40.0
|
14
|
5
|
25.3
|
11
|
4
|
1
|
3
|
57.9
|
21.1
|
6.3
|
15.8
|
- Note: Percentages are among women with known receptor status. Numbers missing are provided in Table 1.
- †Percentages (95% confidences intervals) are 35.3 (32.4 to 38.2) for ERN, 47.2 (44.2 to 50.2) for PRN, and 26.0 (23.3 to 28.6) for HER2P.